Improvement of glucose metabolism following rapid weight loss after bariatric surgery and its impact on reduction of visceral abdominal fat versus free fat muscle

Background: Body fat distribution is highly associated with metabolic disturbances. Skeletal muscle plays an important role in glucose metabolism, as it serves as an important organ for glucose storage in the form of glycogen. In fact, low muscle mass has been associated with metabolic syndrome, type 2 diabetes (T2D), systemic inflammation, and decreased survival. Objectives: To compare the relationship between visceral abdominal fat (VAF) and fat free mass (FFM) with the improved glucose metabolism after bariatric surgery. Setting: University hospital, United States. Methods: A retrospective review was performed of all patients who underwent bariatric surgery between 2011 and 2017 at a university hospital in the United States. In severely obese patients with T2D, we measured the VAF via abdominal computed tomography scan and we calculated the FFM preoperatively and at a 12-month follow-up. Data collected included baseline demographic characteristics and perioperative parameters, such as treatment for hypertension (HTN) and T2D, body mass index (BMI), glycated hemoglobin (HbA1C), glucose, and lipid profile. Results: A total of 25 patients met the inclusion criteria. The average age was 52.5 +/- 11.6 years. The initial BMI was 41.41 +/- 5.7 kg/m(2) and the postoperative BMI was 31.7 +/- 6.9 kg/m(2) (P<.0001). The preoperative VAF volume was 184.6 +/- 90.2 cm(3) and the postoperative VAF volume was 93.8 +/- 46.8 cm(3) at the 12-month follow-up (P<.0001). The preoperative FFM was 55.2 +/- 11.4 kg and the postoperative FFM was 49.1 +/- 12 kg (P<.072). The preoperative HbA1C was 5.8% 6.9%, which decreased postoperatively to 5.3% +/- .4% at the 12-month follow-up (P<.013). Conclusion: Bariatric surgery has been demonstrated to be an effective treatment modality for severe obesity and T2D. Our results suggest that at 12 months, there is a reduction in VAF and HbA1C without a significant loss of FFM. Further prospective studies are needed to better understand these findings. (C) 2021 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.